福蒙尼丁通过诱导铁亡和重建免疫微环境来增强骨髓瘤中西斯普拉丁化疗的敏感性
Yun Liu1, Tianyu Xie2, Jiming Liang1
1Department of Spine and Bone disease, the First Affiliated Hospital of Guangxi Medical University, 530021, Nanning, China.
概括
福蒙尼丁通过抑制铁亡和重编程瘤免疫微观环境来增强骨髓瘤中西斯普拉丁的敏感性. 这种新的方法提供了一种有希望的策略,以克服化疗不敏感性并改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 骨肉瘤由于化疗不敏感而表现出很低的生存率,西斯的疗效有限.
- 开发增强思普拉丁敏感性的策略对于改善骨髓瘤患者的治疗结果至关重要.
研究的目的:
- 调查生物活性化合物formononetin在敏感化骨髓瘤细胞对西斯丁的潜力.
- 阐明福莫诺尼丁对西斯普拉丁敏感性的作用背后的分子机制.
主要方法:
- 利用患者衍生异种移植 (PDX) 模型的骨髓瘤来评估组合的诺尼丁和西斯普拉丁治疗.
- 在瘤组织上进行单细胞RNA测序和单细胞ATAC测序,以分析分子变化.
- 分析了大量的人类和小鼠细胞,以评估治疗对西斯普拉丁敏感性和瘤免疫微环境的影响.
主要成果:
- 骨肉瘤中西斯普拉丁不敏感性与铁亡有关;福蒙尼丁通过抑制MAZ/GPX4轴并诱导铁亡来逆转这种情况.
- 甲诺丁通过调节瘤免疫微环境,增加NK细胞活性,减少耗尽的T细胞和中性粒细胞来增强司胺的敏感性.
- 在PDX模型中,用福莫诺尼丁和西斯普拉丁联合治疗证明了治疗效果的改善.
结论:
- 福莫诺尼丁被确定为第一个在骨髓瘤中增强西斯普拉丁敏感性的化合物.
- 在PDX模型中单细胞测序分析揭示了formonetin的作用机制,包括ferroptosis诱导和免疫微环境重编程.
- 这些发现提供了一种新的治疗策略和机制理解,以对抗骨髓瘤中西斯丁不敏感性.
相关概念视频
Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K


